DK0964873T3 - Anvendelse af glucagonlignende peptid-1 (GLP-1) eller analoger til ophævelse af kataboliske ændringer efter kirurgi - Google Patents

Anvendelse af glucagonlignende peptid-1 (GLP-1) eller analoger til ophævelse af kataboliske ændringer efter kirurgi

Info

Publication number: DK0964873T3
Authority: DK; Denmark
Prior art keywords: glp; analogues; abolish; glucagon; surgery
Prior art date: 1996-08-30

Application number

DK97938640T

Other languages

Danish (da)

English (en)

Inventor

Suad Efendic

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-30

Filing date

1997-08-26

Publication date

2009-03-16

1997-08-26 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2009-03-16 Application granted granted Critical

2009-03-16 Publication of DK0964873T3 publication Critical patent/DK0964873T3/da

Links

230000001925 catabolic effect Effects 0.000 title abstract 2
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 title 1
238000001356 surgical procedure Methods 0.000 title 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 3
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Toxicology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Immunology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK97938640T 1996-08-30 1997-08-26 Anvendelse af glucagonlignende peptid-1 (GLP-1) eller analoger til ophævelse af kataboliske ændringer efter kirurgi DK0964873T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2498296P	1996-08-30	1996-08-30
US08/916,991 US6006753A (en)	1996-08-30	1997-08-21	Use of GLP-1 or analogs to abolish catabolic changes after surgery
PCT/US1997/015042 WO1998008873A1 (fr)	1996-08-30	1997-08-26	Utilisation du peptide-1 semblable au glucagon-1 (glp-1) ou de ses analogues pour supprimer les modifications cataboliques postoperatoires

Publications (1)

Publication Number	Publication Date
DK0964873T3 true DK0964873T3 (da)	2009-03-16

Family

ID=26699130

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97938640T DK0964873T3 (da)	1996-08-30	1997-08-26	Anvendelse af glucagonlignende peptid-1 (GLP-1) eller analoger til ophævelse af kataboliske ændringer efter kirurgi

Country Status (20)

Country	Link
US (1)	US6006753A (fr)
EP (2)	EP0964873B1 (fr)
KR (1)	KR100365606B1 (fr)
CN (1)	CN1235611A (fr)
AT (1)	ATE418996T1 (fr)
AU (1)	AU734140B2 (fr)
BR (1)	BR9712084A (fr)
CA (1)	CA2263802A1 (fr)
DE (1)	DE69739189D1 (fr)
DK (1)	DK0964873T3 (fr)
EA (1)	EA003701B1 (fr)
ES (1)	ES2318861T3 (fr)
IL (1)	IL128740A (fr)
MY (1)	MY121276A (fr)
NO (1)	NO323338B1 (fr)
NZ (1)	NZ334270A (fr)
PL (1)	PL190991B1 (fr)
UA (1)	UA58519C2 (fr)
WO (1)	WO1998008873A1 (fr)
YU (1)	YU10799A (fr)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6852690B1 (en) *	1995-08-22	2005-02-08	Amylin Pharmaceuticals, Inc.	Method and composition for enhanced parenteral nutrition
US20020006899A1 (en) *	1998-10-06	2002-01-17	Pospisilik Andrew J.	Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
DE19616486C5 (de)	1996-04-25	2016-06-30	Royalty Pharma Collection Trust	Verfahren zur Senkung des Blutglukosespiegels in Säugern
US7235627B2 (en)	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de) *	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) *	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de) *	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
EP1588716B1 (fr)	1998-08-06	2011-02-16	Mountain View Pharmaceuticals, Inc.	Conjugués peg-urate oxydase et utilisation assocéee
MY155270A (en) *	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
EP1652531A1 (fr) *	1998-09-24	2006-05-03	Eli Lilly & Company	Utilisation du GLP-1 ou d'un analogue pour le traitement des attaques cérébrales
AU2003270960B2 (en) *	1998-09-24	2006-12-21	Eli Lilly And Company	Use of GLP-1 or Analogs in Treatment of Stroke
US20030176357A1 (en) *	1998-10-06	2003-09-18	Pospisilik Andrew J.	Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
US7259136B2 (en)	1999-04-30	2007-08-21	Amylin Pharmaceuticals, Inc.	Compositions and methods for treating peripheral vascular disease
US6284725B1 (en) *	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
JP4949557B2 (ja) *	1999-03-17	2012-06-13	ノヴォノルディスクアー／エス	ペプチドのアシル化方法及び新規アシル化剤
US6514500B1 (en)	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
WO2000069911A1 (fr)	1999-05-17	2000-11-23	Conjuchem, Inc.	Peptides insulinotropes a longue duree d'action
DE19926233C1 (de)	1999-06-10	2000-10-19	Probiodrug Ges Fuer Arzneim	Verfahren zur Herstellung von Thiazolidin
US9006175B2 (en) *	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
EP2280020B1 (fr)	1999-06-29	2016-02-17	MannKind Corporation	Formulations pharmaceutiques comprenant un peptide complexe avec une dicetopiperazine
EP1076066A1 (fr)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides abaissant le taux de glucose sanguin
DE19940130A1 (de) *	1999-08-24	2001-03-01	Probiodrug Ges Fuer Arzneim	Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
US20060160740A1 (en) *	1999-10-21	2006-07-20	Suad Efendic	Use of GLP-1 or analogs in treatment of stroke
KR100873585B1 (ko) *	2000-03-17	2008-12-11	아지노모토 가부시키가이샤	당뇨병성 합병증용 약제
CN101690815A (zh) *	2000-03-31	2010-04-07	普罗西迪恩有限公司	二肽基肽酶iv酶活性抑制剂的新用途
JP2003530838A (ja)	2000-04-12	2003-10-21	ヒューマンゲノムサイエンシズインコーポレイテッド	アルブミン融合タンパク質
AU2001254621A1 (en)	2000-05-05	2001-11-20	K.U. Leuven R And D	Critical illness neuropathy
CA2395165C (fr)	2000-10-20	2012-05-22	Mario Ehlers	Traitement du myocarde hibernant et de la cardiomiopathie diabetique par un peptide glp-1
US7132104B1 (en)	2000-10-27	2006-11-07	Probiodrug Ag	Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
AU2177302A (en) *	2000-10-27	2002-05-06	Probiodrug Ag	Method for the treatment of neurological and neuropsychological disorders
US6890905B2 (en)	2001-04-02	2005-05-10	Prosidion Limited	Methods for improving islet signaling in diabetes mellitus and for its prevention
WO2002085406A1 (fr) *	2001-04-24	2002-10-31	Restoragen, Inc.	Procedes et compositions pour le traitement d'etats lies a la resistance a l'insuline
US7368421B2 (en)	2001-06-27	2008-05-06	Probiodrug Ag	Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US20030130199A1 (en) *	2001-06-27	2003-07-10	Von Hoersten Stephan	Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
DE10150203A1 (de) *	2001-10-12	2003-04-17	Probiodrug Ag	Peptidylketone als Inhibitoren der DPIV
CN1363654A (zh)	2001-07-19	2002-08-14	上海华谊生物技术有限公司	生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
US6642003B2 (en)	2001-08-02	2003-11-04	Cedars-Sinai Medical Center	Human glucose-dependent insulin-secreting cell line
EP1492525A2 (fr) *	2001-08-16	2005-01-05	Probiodrug AG	Utilisation d'inhibiteurs de la proline endopeptidase pour moduler la concentration d'inositol (1,4,5) triphosphate dependante des cascades de signaux intracellulaires
US6844316B2 (en) *	2001-09-06	2005-01-18	Probiodrug Ag	Inhibitors of dipeptidyl peptidase I
JP2005523877A (ja) *	2001-10-01	2005-08-11	イーライ・リリー・アンド・カンパニー	重病に関連する死亡率および罹患率の低減化方法
WO2003059934A2 (fr) *	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Proteines de fusion d'albumine
ES2425738T3 (es)	2001-12-21	2013-10-17	Human Genome Sciences, Inc.	Proteínas de fusión de la albúmina
US20030199445A1 (en) *	2002-02-07	2003-10-23	Knudsen Lotte Bjerre	Use of GLP-1 compound for treatment of critically ill patients
AU2003203146A1 (en) *	2002-02-07	2003-09-02	Novo Nordisk A/S	Use of glp-1 compound for treatment of critically ill patients
AU2003208945B2 (en) *	2002-02-20	2008-05-01	Emisphere Technologies, Inc	Method for administering GLP-1 molecules
DE60335608D1 (de)	2002-02-27	2011-02-17	Pharmain Corp	Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en)	2002-02-27	2009-12-22	Pharmain Corporation	Compositions for delivery of therapeutics and other materials
US20050260259A1 (en) *	2004-04-23	2005-11-24	Bolotin Elijah M	Compositions for treatment with glucagon-like peptide, and methods of making and using the same
DK1480961T3 (da) *	2002-02-28	2007-05-07	Prosidion Ltd	Glutaminylbaserede DPIV-inhibitorer
US7141240B2 (en) *	2002-03-12	2006-11-28	Cedars-Sinai Medical Center	Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
ES2425392T3 (es)	2002-03-20	2013-10-15	Mannkind Corporation	Cartucho para un aparato de inhalación
US20030232761A1 (en) *	2002-03-28	2003-12-18	Hinke Simon A.	Novel analogues of glucose-dependent insulinotropic polypeptide
AU2003223420A1 (en) *	2002-04-01	2003-10-20	Healthetech, Inc.	System and method of determining an individualized drug administration dosage
WO2003092614A2 (fr) *	2002-05-02	2003-11-13	Hickle Randall S	Systeme et procedes d'elimination de lipides du corps
EP2028192A1 (fr)	2002-07-04	2009-02-25	Zealand Pharma A/S	GLP-1 et procédé de traitement du diabète
US8377869B2 (en) *	2007-10-24	2013-02-19	Mannkind Corporation	Method of preventing adverse effects by GLP-1
US20080260838A1 (en) *	2003-08-01	2008-10-23	Mannkind Corporation	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20040033051A1 (en) *	2002-08-16	2004-02-19	Ip Kiril Kun Wan	Method and system for producing and displaying visual presentations which inhibit off-screen duplication
US20040058876A1 (en) *	2002-09-18	2004-03-25	Torsten Hoffmann	Secondary binding site of dipeptidyl peptidase IV (DP IV)
AU2003293311A1 (en) *	2002-09-18	2004-04-23	Prosidion Ltd.	Secondary binding site of dipeptidyl peptidase iv (dp iv)
US7273921B2 (en)	2002-09-25	2007-09-25	Novo Nordisk A/S	Method for producing acylated peptides
KR20050083713A (ko) *	2002-10-02	2005-08-26	질랜드 파마 에이/에스	안정화된 엑센딘-4 화합물
EP1594530A4 (fr)	2003-01-22	2006-10-11	Human Genome Sciences Inc	Proteines hybrides d'albumine
KR20050122220A (ko)	2003-03-25	2005-12-28	다케다 샌디에고, 인코포레이티드	디펩티딜 펩티다제 억제제
WO2004094823A2 (fr)	2003-04-23	2004-11-04	Biovalve Technologies, Inc.	Pompe hydraulique d'administration de medicaments sur de longues durees
KR20120035203A (ko) *	2003-05-05	2012-04-13	프로비오드룩 아게	글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
ATE462432T1 (de) *	2003-05-05	2010-04-15	Probiodrug Ag	Glutaminylcyclase-hemmer
US7638638B2 (en)	2003-05-14	2009-12-29	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
AU2004251145C1 (en)	2003-06-12	2011-04-14	Eli Lilly And Company	GLP-1 analog fusion proteins
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US20050070531A1 (en)	2003-08-13	2005-03-31	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
US7790734B2 (en)	2003-09-08	2010-09-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2005039548A2 (fr) *	2003-10-15	2005-05-06	Probiodrug Ag	Utilisation d'effecteurs de cyclases du glutaminyle et du glutamate
US20050171112A1 (en) *	2003-11-03	2005-08-04	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
US20100099721A1 (en) *	2003-11-03	2010-04-22	Probiodrug Ag	Novel compounds for the treatment of neurological disorders
US20060286129A1 (en) *	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
WO2005075436A2 (fr)	2004-02-05	2005-08-18	Probiodrug Ag	Nouveaux inhibiteurs de la glutaminyl-cyclase
PL1729795T3 (pl) *	2004-02-09	2016-08-31	Human Genome Sciences Inc	Białka fuzyjne albuminy
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2005095381A1 (fr)	2004-03-15	2005-10-13	Takeda Pharmaceutical Company Limited	Inhibiteurs de la dipeptidyle peptidase
PT2100904E (pt)	2004-04-23	2010-09-24	Conjuchem Biotechnologies Inc	Fase sólida para utilização num método para a purificação de conjugados de albumina
WO2005118555A1 (fr)	2004-06-04	2005-12-15	Takeda Pharmaceutical Company Limited	Inhibiteurs de la dipeptidyl peptidase
US9089636B2 (en) *	2004-07-02	2015-07-28	Valeritas, Inc.	Methods and devices for delivering GLP-1 and uses thereof
WO2006019965A2 (fr)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Inhibiteurs de la dipeptidyl peptidase
JP5078014B2 (ja)	2004-08-20	2012-11-21	マンカインドコーポレイション	ジケトピペラジン合成の触媒反応
PL2322180T3 (pl)	2004-08-23	2015-10-30	Mannkind Corp	Sole diketopiperazyny do dostarczania leków
EP1828192B1 (fr)	2004-12-21	2014-12-03	Takeda Pharmaceutical Company Limited	Inhibiteurs de dipeptidyle peptidase
KR20070102694A (ko) *	2005-01-31	2007-10-19	아지노모토 가부시키가이샤	혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
US8148123B2 (en)	2005-04-11	2012-04-03	Savient Pharmaceuticals, Inc.	Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8946149B2 (en) *	2005-04-11	2015-02-03	Amylin Pharmaceuticals, Llc	Use of exendin and analogs thereof to delay or prevent cardiac remodeling
AU2006235495B2 (en)	2005-04-11	2012-04-12	Horizon Therapeutics Usa, Inc.	Variant forms of urate oxidase and use thereof
SG161248A1 (en)	2005-04-11	2010-05-27	Savient Pharmaceuticals Inc	A variant form of urate oxidase and use thereof
BRPI0609676A2 (pt)	2005-05-13	2011-10-18	Lilly Co Eli	composto de glp-1 peguilado,e, uso do mesmo
KR20080028981A (ko)	2005-06-30	2008-04-02	소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스.	Ｇｌｐ-1 약학 조성물
CA2622472C (fr)	2005-09-14	2013-11-19	Takeda Pharmaceutical Company Limited	Inhibiteurs de la dipeptidyl peptidase permettant de traiter le diabete
US20070060529A1 (en) *	2005-09-14	2007-03-15	Christopher Ronald J	Administration of dipeptidyl peptidase inhibitors
CN104324366B (zh)	2005-09-14	2016-10-05	曼金德公司	以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
KR101368988B1 (ko)	2005-09-16	2014-02-28	다케다 야쿠힌 고교 가부시키가이샤	디펩티딜 펩티다제 억제제
US8039432B2 (en)	2005-11-09	2011-10-18	Conjuchem, Llc	Method of treatment of diabetes and/or obesity with reduced nausea side effect
US20070141145A1 (en)	2005-12-19	2007-06-21	Pharmaln Ltd.	Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
KR20080096809A (ko)	2006-02-22	2008-11-03	맨카인드 코포레이션	디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
WO2007112347A1 (fr)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Inhibiteurs de la dipeptidyl peptidase
WO2007115039A2 (fr)	2006-03-30	2007-10-11	Valeritas, Llc	dispositif d'acheminement de fluide à cartouches multiples
JP5791228B2 (ja) *	2006-09-13	2015-10-07	武田薬品工業株式会社	２−６−（３−アミノ−ピペリジン−１−イル）−３−メチル−２，４−ジオキソ−３，４−ジヒドロ−２ｈ−ピリミジン−１−イルメチル−４−フルオロ−ベンゾニトリルの使用
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
JP2009019027A (ja)	2007-07-16	2009-01-29	Hanmi Pharmaceutical Co Ltd	アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
US7960336B2 (en)	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en)	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
RU2467741C2 (ru) *	2007-10-24	2012-11-27	Маннкайнд Корпорейшн	Доставка активных веществ
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
US20090176892A1 (en) *	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
MY155524A (en)	2008-06-13	2015-10-30	Mannkind Corp	A dry powder inhaler and system for drug delivery
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
KR101628410B1 (ko)	2008-06-20	2016-06-08	맨카인드 코포레이션	흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
TWI532497B (zh)	2008-08-11	2016-05-11	曼凱公司	超快起作用胰島素之用途
CR20170369A (es)	2008-10-17	2017-11-01	Sanofi Aventis Deutschland	COMBINACIÓN DE UNA INSULINA Y UN AGONISTA DE GLP-1 (Divisional 2011-0188)
US20100144140A1 (en) *	2008-12-10	2010-06-10	Novellus Systems, Inc.	Methods for depositing tungsten films having low resistivity for gapfill applications
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (fr)	2009-02-09	2010-08-11	Ipsen Pharma S.A.S.	Compositions pharmaceutiques analogues au GLP-1
DK2405963T3 (da)	2009-03-11	2013-12-16	Mannkind Corp	Apparat, system og fremgangsmåde til at måle modstand i en inhalator
US8614185B2 (en) *	2009-05-04	2013-12-24	Centocor Ortho Biotech Inc.	Fusion proteins of alpha-MSH derivatives and Fc
JP5751641B2 (ja)	2009-05-06	2015-07-22	ヤンセンバイオテツク，インコーポレーテツド	メラノコルチン受容体結合コンジュゲート
KR20180079458A (ko)	2009-06-12	2018-07-10	맨카인드 코포레이션	한정된 비표면적을 갖는 디케토피페라진 마이크로입자
EP2446260B1 (fr)	2009-06-25	2018-12-26	Horizon Pharma Rheumatology LLC	Procédés et nécessaires pour prédire un risque de réaction à la perfusion et une perte de réponse médiée par des anticorps par surveillance de l'acide urique sérique pendant un traitement à l'uricase pegylée
US9016147B2 (en)	2009-11-03	2015-04-28	Mannkind Corporation	Apparatus and method for simulating inhalation efforts
WO2011058082A1 (fr)	2009-11-13	2011-05-19	Sanofi-Aventis Deutschland Gmbh	Composition pharmaceutique comprenant un agoniste de glp-1 et de la méthionine
PL2498802T3 (pl)	2009-11-13	2015-06-30	Sanofi Aventis Deutschland	Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
EP2555791B1 (fr)	2010-04-09	2017-11-01	Sinai Health System	Méthodes de traitement de troubles du tractus gastro-intestinal au moyen d'un agoniste glp-1
EA023925B1 (ru)	2010-04-27	2016-07-29	Зилэнд Фарма А/С	Пептидные конъюгаты агонистов рецептора glp-1 и их применение
BR112012033060A2 (pt)	2010-06-21	2018-02-27	Mannkind Corp	métodos de sistema de liberação de fármaco em pó seco
JP2013530993A (ja)	2010-07-02	2013-08-01	アンジオケムインコーポレーテッド	治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
SG187904A1 (en)	2010-08-30	2013-04-30	Sanofi Aventis Deutschland	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
AU2012236150B2 (en)	2011-04-01	2016-03-31	Mannkind Corporation	Blister package for pharmaceutical cartridges
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (fr)	2011-06-17	2012-12-20	Mannkind Corporation	Microparticules de dicétopipérazine de capacité élevée
EP2750699B1 (fr)	2011-08-29	2015-07-22	Sanofi-Aventis Deutschland GmbH	Combinaison pharmaceutique destinée à être utilisée dans le contrôle de la glycémie chez des patients souffrant du diabète de type 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AU2012328885B2 (en)	2011-10-24	2017-08-31	Mannkind Corporation	Methods and compositions for treating pain
WO2013064669A1 (fr)	2011-11-03	2013-05-10	Zealand Pharma A/S	Conjugués de peptide agoniste du récepteur du glp-1 et de gastrine
SG10201605800UA (en)	2012-07-12	2016-09-29	Mannkind Corp	Dry powder drug delivery system and methods
EP2875043B1 (fr)	2012-07-23	2016-12-21	Zealand Pharma A/S	Analogues du glucagon
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
TWI641381B (zh)	2013-02-04	2018-11-21	法商賽諾菲公司	胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
AU2014228415B2 (en)	2013-03-15	2018-08-09	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
KR102465025B1 (ko)	2013-07-18	2022-11-09	맨카인드 코포레이션	열-안정성 건조 분말 약제학적 조성물 및 방법
WO2015021064A1 (fr)	2013-08-05	2015-02-12	Mannkind Corporation	Appareil d'insufflation et procédés
CN104371019B (zh)	2013-08-13	2019-09-10	鸿运华宁（杭州）生物医药有限公司	一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
AU2014336098B2 (en)	2013-10-17	2018-05-10	Boehringer Ingelheim International Gmbh	Acylated glucagon analogues
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
WO2015067716A1 (fr)	2013-11-06	2015-05-14	Zealand Pharma A/S	Composés agonistes triples glucagon-glp-1-gip
WO2015067715A2 (fr)	2013-11-06	2015-05-14	Zealand Pharma A/S	Composés agonistes doubles de gip et glp-1 et procédés associés
CN105899191B (zh)	2014-01-09	2020-06-16	赛诺菲	胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
MX2016008977A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas de insulina aspart estabilizadas.
JP6641280B2 (ja)	2014-01-09	2020-02-05	サノフイＳａｎｏｆｉ	インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
EP3212218B1 (fr)	2014-10-29	2021-06-30	Zealand Pharma A/S	Composés agonistes de gip et procédés associés
EP3229828B1 (fr)	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Formulation à rapport fixe d'insuline glargine/lixisenatide
KR101825048B1 (ko)	2014-12-31	2018-02-05	주식회사 제넥신	GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
PL3257524T3 (pl)	2015-02-11	2021-03-08	Gmax Biopharm Llc	Stabilny preparat farmaceutyczny w postaci roztworu białka fuzyjnego przeciwciała przeciwko glp-1r
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
US10336802B2 (en)	2015-04-16	2019-07-02	Zealand Pharma A/S	Acylated glucagon analogue
WO2018104561A1 (fr)	2016-12-09	2018-06-14	Zealand Pharma A/S	Agonistes doubles de glp-1/glp-2 acylés
RS65380B1 (sr)	2017-08-24	2024-04-30	Novo Nordisk As	Glp-1 kompozicije i njihova upotreba
CN117003874A (zh)	2018-03-20	2023-11-07	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
WO2020160322A1 (fr)	2019-01-30	2020-08-06	Horizon Pharma Rheumatology Llc	Tolérisation réduisant l'intolérance à la pegloticase et prolongeant l'effet d'abaissement de l'urate (triple)
CN112521501A (zh)	2019-09-18	2021-03-19	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
IL294520A (en)	2020-02-18	2022-09-01	Novo Nordisk As	Pharmaceutical formulations
CN119744271A (zh)	2022-09-08	2025-04-01	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与fgf21的融合蛋白，以及其药物组合物和应用
US12269875B2 (en)	2023-08-03	2025-04-08	Jeff R. Peterson	Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5118666A (en) *	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
US5120712A (en) *	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5545618A (en) *	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
JP3262329B2 (ja) *	1990-01-24	2002-03-04	アイ．バックレイ，ダグラス	糖尿病治療に有用なｇｌｐ―１アナログ
PL176007B1 (pl) *	1992-06-15	1999-03-31	Scios Inc	Nowe pochodne polipeptydu GLP-1
NZ250844A (en) *	1993-04-07	1996-03-26	Pfizer	Treatment of non-insulin dependant diabetes with peptides; composition
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use

1997
- 1997-08-21 US US08/916,991 patent/US6006753A/en not_active Expired - Lifetime
- 1997-08-26 UA UA99021151A patent/UA58519C2/uk unknown
- 1997-08-26 BR BR9712084A patent/BR9712084A/pt not_active Application Discontinuation
- 1997-08-26 PL PL332003A patent/PL190991B1/pl not_active IP Right Cessation
- 1997-08-26 WO PCT/US1997/015042 patent/WO1998008873A1/fr active IP Right Grant
- 1997-08-26 EP EP97938640A patent/EP0964873B1/fr not_active Expired - Lifetime
- 1997-08-26 KR KR10-1999-7001611A patent/KR100365606B1/ko not_active Expired - Fee Related
- 1997-08-26 AT AT97938640T patent/ATE418996T1/de not_active IP Right Cessation
- 1997-08-26 AU AU40926/97A patent/AU734140B2/en not_active Ceased
- 1997-08-26 CA CA002263802A patent/CA2263802A1/fr not_active Abandoned
- 1997-08-26 ES ES97938640T patent/ES2318861T3/es not_active Expired - Lifetime
- 1997-08-26 CN CN97199222A patent/CN1235611A/zh active Pending
- 1997-08-26 NZ NZ334270A patent/NZ334270A/xx unknown
- 1997-08-26 DK DK97938640T patent/DK0964873T3/da active
- 1997-08-26 EP EP08159135A patent/EP2181712A1/fr not_active Withdrawn
- 1997-08-26 DE DE69739189T patent/DE69739189D1/de not_active Expired - Lifetime
- 1997-08-26 EA EA199900169A patent/EA003701B1/ru not_active IP Right Cessation
- 1997-08-26 IL IL128740A patent/IL128740A/en not_active IP Right Cessation
- 1997-08-26 YU YU10799A patent/YU10799A/sh unknown
- 1997-08-28 MY MYPI97003977A patent/MY121276A/en unknown
1999
- 1999-02-25 NO NO19990915A patent/NO323338B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR100365606B1 (ko)	2003-02-07
IL128740A (en)	2007-08-19
NO323338B1 (no)	2007-04-02
PL332003A1 (en)	1999-08-16
ATE418996T1 (de)	2009-01-15
BR9712084A (pt)	1999-08-24
CA2263802A1 (fr)	1998-03-05
PL190991B1 (pl)	2006-02-28
KR20000035895A (ko)	2000-06-26
NZ334270A (en)	2000-07-28
UA58519C2 (uk)	2003-08-15
ES2318861T3 (es)	2009-05-01
EP2181712A1 (fr)	2010-05-05
EP0964873A4 (fr)	2002-07-03
WO1998008873A1 (fr)	1998-03-05
CN1235611A (zh)	1999-11-17
MY121276A (en)	2006-01-28
US6006753A (en)	1999-12-28
AU734140B2 (en)	2001-06-07
NO990915D0 (no)	1999-02-25
DE69739189D1 (de)	2009-02-12
EP0964873A1 (fr)	1999-12-22
EA199900169A1 (ru)	1999-08-26
EP0964873B1 (fr)	2008-12-31
AU4092697A (en)	1998-03-19
EA003701B1 (ru)	2003-08-28
IL128740A0 (en)	2000-01-31
YU10799A (sh)	2003-04-30
NO990915L (no)	1999-04-13

Publication	Publication Date	Title
DK0964873T3 (da)	2009-03-16	Anvendelse af glucagonlignende peptid-1 (GLP-1) eller analoger til ophævelse af kataboliske ændringer efter kirurgi
DK36392D0 (da)	1992-03-19	Anvendelse af kemisk forbindelse
EA200300026A1 (ru)	2003-04-24	Аналоги глюкагоноподобного пептида-1
BG103192A (en)	1999-09-30	Substituted 6,6-hetero-bicyclic derivatives
DK0527824T3 (da)	1995-06-19	Anvendelse af en kombination af ioniske og nonioniske tensider
DE69530791D1 (de)	2003-06-18	Protein tyrosine kinase (pyk2), ihre cdna klonierung und ihre verwendungen
DK0946191T3 (da)	2003-07-14	Anvendelse af GLP-1-analoge og -derivater indgivet perifert til regulering af fedme
WO2003058203A3 (fr)	2007-02-01	Analogues de peptide-1 de type glucagon d'extension
FI954941A7 (fi)	1996-04-19	Glukagonintapaisia insuliinitrooppisia peptidianalogeja, koostumuksia ja käyttömenetelmiä
CL2004001102A1 (es)	2005-04-29	Compuestos derivados de 2-amino-4-bicicloamino-1,3,5-triazinas; composicion herbicida que los contiene; procedimiento de preparacion; uso de dichos compuestos; y compuestos intermediarios.
TW200626613A (en)	2006-08-01	Analogues of GLP-1
IL143481A0 (en)	2002-04-21	Glp-1 analogues
MX9203326A (es)	1993-06-01	Tijeras de uso general.
DK36283D0 (da)	1983-01-31	Multifunktionelle klonende vektorer til anvendelse i streptomyces, bacillus og e.coli og fremgangsmade til fremstilling af sadanne vektorer
JPS5291852A (en)	1977-08-02	Azetidinones
ES2016292B3 (es)	1990-11-01	Medio protector de madera.
MX9207429A (es)	1993-06-01	Nuevo uso de derivados de aminoacido.
NO954892L (no)	1995-12-01	Heterosyklisk kjemi
DK0830143T3 (da)	2003-06-16	Anvendelse af leukæmiinhiberende faktor og endothelinantagonister
EP1359159A3 (fr)	2004-07-21	Analogues du GLP-1
DE58901750D1 (de)	1992-08-06	Spannhuelse fuer elektroden in brennern, insbesondere wig-brennern.
ES1035679Y (es)	1997-11-16	Mesa de trabajo de carpinteria.
FR2717355B1 (fr)	1996-06-21	Table escamotable à stabilité optimisée.
HUP0000271A3 (en)	2000-10-30	Use of glucagon-like peptide-1 (glp-1) or analogs to abolish catabolic changes after surgery
ES1026044Y (es)	1994-09-16	Mesa plegable perfeccionada.